Venrock Healthcare Capital Partners III, L.P. (Koh Bong Y, Shah Nimish P) purchased $224K of LYCA (indirect holdings)
Venrock Healthcare Capital Partners III, L.P. purchased 8,305 indirectly-held shares of Lycia Therapeutics, Inc. (LYCA) at $26.95 ($0.22M total) on 2026-11-02. Filed jointly with VHCP Co-Investment Holdings III, LLC (10% owner), VHCP Management III, LLC (10% owner), Venrock Healthcare Capital Partners EG, L.P. (10% owner), VHCP Management EG, LLC (10% owner), Venrock Healthcare Capital Partners XP, L.P. (10% owner), VHCP Management XP, LLC (10% owner), Koh Bong Y (10% owner) and Shah Nimish P (10% owner).
How this was made
The 30-second read
Why it matters
The insider purchase is a positive signal but its small size limits immediate price impact.
Market read
Minor insider buying; unlikely to drive significant trading activity.
What to watch
Potential upcoming clinical data releases could amplify the significance of insider buying.
Background
Form 4 filings provide primary disclosure of insider transactions. This filing reports a modest purchase by a venture capital affiliate.
Ticker impact
Venrock Healthcare Capital Partners III purchased 8,305 shares of Lycia Therapeutics at $26.95, increasing its stake to over 6.8 million shares.
slight upward pressure as the market prices in insider confidence
The transaction size (~$224K) is modest for a public biotech; while insider buying is positive, the amount is unlikely to move the stock significantly.
Market effects
Minimal effect on the broader biotech sector.
No notable regional impact.
Limited to investors tracking insider activity.
Counterpoint
The purchase may be a routine portfolio rebalancing rather than a strong endorsement.
Key entities
- CompanyLycia Therapeutics, Inc.
Biotech company developing therapies for rare diseases.
- InvestorVenrock Healthcare Capital Partners III, L.P.
Venture capital fund affiliated with Venrock.